S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 83 200 KRW -2.92% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ST Pharm Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Total Liabilities & Equity
â‚©675.4B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Total Liabilities & Equity
â‚©16.3T
CAGR 3-Years
35%
CAGR 5-Years
23%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Total Liabilities & Equity
â‚©171.7B
CAGR 3-Years
32%
CAGR 5-Years
31%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Total Liabilities & Equity
â‚©67B
CAGR 3-Years
-5%
CAGR 5-Years
1%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Total Liabilities & Equity
â‚©189.5B
CAGR 3-Years
-11%
CAGR 5-Years
6%
CAGR 10-Years
27%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Total Liabilities & Equity
â‚©26B
CAGR 3-Years
-24%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
97 768.06 KRW
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
675.4B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Total Liabilities & Equity amounts to 675.4B KRW.

What is ST Pharm Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
15%

Over the last year, the Total Liabilities & Equity growth was 4%. The average annual Total Liabilities & Equity growth rates for ST Pharm Co Ltd have been 11% over the past three years , 15% over the past five years .

Back to Top